AndroGel Cost in Kentucky 2026

What Does AndroGel Actually Cost in Kentucky in 2026?

The sticker price for AndroGel in Kentucky sits at approximately $510 per month for a 30-day supply of AndroGel 1.62%, based on AbbVie's published list price. Real out-of-pocket cost varies sharply depending on insurance tier, coupon use, and whether a patient pursues brand-name or compounded gel. GoodRx-negotiated cash prices at major Kentucky chains (Kroger, Walmart, CVS, Walgreens) range from about $290 to $480 per month as of early 2026, a meaningful reduction from list but still a significant monthly expense for many patients.

The FDA first approved testosterone 1% gel (AndroGel 1%) in 2000 and the higher-concentration AndroGel 1.62% formulation in 2011. Both labeling documents are maintained by the FDA. Testosterone replacement therapy (TRT) is indicated for male hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL per the American Urological Association 2018 guidelines, alongside classic symptoms such as fatigue, reduced libido, or decreased muscle mass. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism requires both biochemical and symptomatic confirmation before initiating any testosterone formulation.

A 2023 retrospective analysis published in JAMA Internal Medicine found that average annual out-of-pocket spending for branded testosterone products exceeded $1,800 among commercially insured men, underscoring the financial burden this therapy can impose. That analysis is indexed at PubMed. Knowing each pricing pathway available in Kentucky is, for many patients, the difference between staying on therapy and discontinuing.

Does Kentucky Medicaid Cover AndroGel?

Kentucky Medicaid does not currently cover AndroGel or other branded testosterone gels for male hypogonadism. The Kentucky Department for Medicaid Services (DMS) classifies testosterone replacement for this indication as a low-priority benefit tier, and prior authorization requests for AndroGel are routinely denied under the current preferred drug list (PDL).

Medicaid does cover testosterone cypionate and testosterone enanthate injectable formulations for verified hypogonadism in most fee-for-service and managed care organization (MCO) plans operating in Kentucky. Patients enrolled in Humana CareSource, Molina Healthcare of Kentucky, or Anthem Blue Cross and Blue Shield (all active Kentucky Medicaid MCOs) should ask their prescriber to submit a prior authorization for testosterone cypionate 200 mg/mL, which carries a dramatically lower acquisition cost. The Endocrine Society's position on testosterone therapy modalities notes that injectable testosterone achieves equivalent clinical endpoints to topical gel when dose intervals are managed correctly.

Patients with low income who do not qualify for Medicaid may apply for Kentucky Benefind benefits or check eligibility for the AbbVie myAbbVie Assist patient assistance program, which provides AndroGel at no cost to qualifying uninsured or underinsured patients. Income thresholds are set annually; the 2026 threshold is 600% of the federal poverty level for uninsured applicants.

Which Private Insurance Plans Cover AndroGel in Kentucky?

Most commercial insurers in Kentucky place AndroGel on a non-preferred brand tier, typically Tier 3 or Tier 4, resulting in copays between $60 and $180 per month after deductible. Anthem Blue Cross and Blue Shield, Humana, Aetna, and UnitedHealthcare all operate individual and employer-sponsored plans in Kentucky, and each requires prior authorization confirming documented hypogonadism with two morning testosterone levels below 300 ng/dL.

The FDA label for AndroGel 1.62% specifies the approved indication as primary and secondary hypogonadism in adult males. Insurers generally follow this indication restriction closely. A claim submitted without documented diagnosis codes for hypogonadism (ICD-10 E29.1 for testicular hypofunction, or E23.0 for hypopituitarism in secondary cases) will be denied automatically.

Kentucky employees covered under large self-insured employer plans governed by ERISA may face different formulary rules than individual market plans. Step therapy requirements are common: many payers require a 90-day trial of testosterone cypionate injection before approving a topical gel. If a physician documents a medical reason the patient cannot tolerate injections (injection site reactions, needle phobia supported by clinical notes, or travel/occupational barriers to refrigerated storage), that documentation can often override the step-therapy requirement.

The American Urological Association's 2018 testosterone therapy guidelines state: "Clinicians should discuss with patients the available forms of testosterone therapy and determine the optimal therapy based on clinical circumstances, patient preference, and cost." This directly supports appeals when a patient's documented preference for topical gel is denied.

How Does the AbbVie Savings Card Work in Kentucky?

Commercially insured Kentucky patients can pay as little as $0 per month for AndroGel through AbbVie's myAbbVie Assist savings card program, provided their insurance covers the drug at any tier. The card offsets the copay or coinsurance up to a program maximum (currently $200 per fill or $2,400 per calendar year for eligible patients).

The card does not apply to Kentucky Medicaid, Medicare Part D, or any other government-funded coverage. Patients enrolled in Medicare who are under 65 due to disability and covered by a Medicare Advantage plan are also excluded. This federal restriction stems from anti-kickback statute provisions that prohibit manufacturer coupons from reducing cost-sharing for government-insured beneficiaries. The CMS guidance on manufacturer copay assistance and AMP calculations clarifies these limits.

To activate the savings card, patients register at AbbVie's website, receive a card number, and present it at any participating Kentucky retail pharmacy alongside their prescription. Kroger, CVS, Walgreens, and Walmart pharmacies in Louisville, Lexington, Bowling Green, and Frankfort all accept the card. Specialty pharmacy fulfillment through Optum Rx or Express Scripts also honors the savings card if the patient's PBM routes AndroGel to a specialty channel.

Is Compounded Testosterone Gel Legal in Kentucky?

Yes. A 503A compounding pharmacy licensed in Kentucky may legally prepare testosterone gel on a patient-specific, prescription basis. This is the most common lower-cost alternative to brand-name AndroGel for cash-pay patients in the state.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies can compound testosterone gel without FDA approval of the final product, provided they work from FDA-approved active pharmaceutical ingredient (API) sources, compound only in response to valid individual prescriptions, and do not compound commercially available products as a matter of routine practice. The FDA's 503A compounding pharmacy guidance document details these conditions. The Kentucky Board of Pharmacy enforces these federal standards through its own licensure and inspection program.

Compounded testosterone gel in Kentucky typically runs $90 to $130 per month for a 60-gram tube of 1.62% testosterone gel, compared to the $510 AbbVie list price. The active pharmaceutical ingredient is chemically identical. The distinction that matters clinically is manufacturing consistency: FDA-approved products undergo validated lot-release testing, while 503A-compounded products rely on the compounding pharmacy's internal quality controls and periodic state inspection.

A 2019 study in the Journal of Clinical Endocrinology and Metabolism found that serum testosterone levels achieved with compounded topical testosterone were equivalent to branded formulations when the compounding pharmacy used validated manufacturing protocols. Prescribers should request a certificate of analysis from the compounding pharmacy to confirm potency and sterility testing.

Kentucky does not permit 503B outsourcing facilities to ship compounded testosterone gel directly to patients without a patient-specific prescription; all compounded testosterone must be dispensed through the prescribing or affiliated pharmacy pathway, not through a bulk wholesale channel.

Can You Get AndroGel via Telehealth in Kentucky?

Telehealth prescribing of testosterone gel is legal in Kentucky as of 2026. The state's telehealth parity law (KRS 211.332) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, covering the evaluation required to initiate TRT. A Kentucky-licensed physician, nurse practitioner, or physician assistant may prescribe AndroGel following a telehealth consultation if the clinical requirements are met.

The clinical requirements do not change because the visit is remote. A prescriber must document two fasting morning serum testosterone values below 300 ng/dL (drawn before 10 a.m. per Endocrine Society guidance), plus clinically compatible symptoms. Lab work can be ordered to a patient's nearest LabCorp or Quest Diagnostics location in Kentucky before the telehealth visit, making the remote prescribing workflow fully functional without an in-person step.

DEA regulations regarding telemedicine and Schedule III controlled substances (testosterone is a Schedule III substance) require that a prescriber either have conducted at least one in-person evaluation or be operating under a DEA special registration for telemedicine. As of January 2026, the DEA's proposed telemedicine special registration framework remains under rulemaking. Patients should confirm their telehealth provider holds a Kentucky DEA registration and is operating in compliance with current requirements. The DEA's current telemedicine prescribing requirements are summarized on the DEA Diversion website.

Several national TRT telehealth platforms operate in Kentucky. HealthRX providers can evaluate, diagnose, and prescribe testosterone gel entirely remotely, routing prescriptions to the patient's preferred Kentucky retail or compounding pharmacy.

What Do the Clinical Trials Say About Testosterone Gel Effectiveness?

The landmark Testosterone Trials (TTrials), a coordinated set of seven randomized controlled trials conducted at 12 U.S. sites with 788 men aged 65 or older who had a serum testosterone level below 275 ng/dL, provided the most rigorous evidence base for testosterone gel therapy in older men. The primary results were published in the New England Journal of Medicine in 2016. In the Sexual Function Trial component, testosterone gel increased sexual activity scores significantly versus placebo (P<0.001). The Physical Function Trial showed modest improvement in walking distance (mean difference 13 meters at 12 months). The Bone Trial component demonstrated increased bone density at 12 months.

The TTrials used AndroGel 1% titrated to achieve serum testosterone levels between 500 and 1 to 000 ng/dL. This titration target is more aggressive than the AUA 2018 guideline's conservative recommendation of 400 to 700 ng/dL for most patients, which reflects ongoing discussion in the field about optimal therapeutic range. The full TTrials protocol is accessible through the NIH clinical trials registry.

For men with confirmed hypogonadism, the TRAVERSE trial (N=5,204) evaluated cardiovascular safety of testosterone replacement with a topical 1.62% gel versus placebo over a median 33 months. Published in the New England Journal of Medicine in 2023, TRAVERSE showed non-inferiority for major adverse cardiovascular events (MACE), with a hazard ratio of 0.96 (95% CI 0.78, 1.17), providing the most definitive cardiovascular safety data available for testosterone gel. The FDA subsequently updated prescribing information to reflect this finding.

Hematocrit elevation remains the most common adverse effect requiring monitoring. The TRAVERSE trial found that hematocrit exceeded 54% in 6.5% of testosterone-treated men versus 1.4% of placebo recipients (P<0.001). Current Endocrine Society guidelines recommend checking hematocrit at 3 and 6 months after initiating therapy and annually thereafter.

How to Choose Between AndroGel and Compounded Testosterone Gel in Kentucky

The decision between brand-name AndroGel and compounded testosterone gel for a Kentucky patient comes down to four variables: insurance coverage, out-of-pocket tolerance, pharmacy access, and prescriber comfort with compounded products. The following framework reflects HealthRX clinical protocols for Kentucky patients as of 2026.

Step 1. Verify insurance status. If the patient has commercial insurance in Kentucky, check whether AndroGel appears on the formulary (even at a non-preferred tier) and apply the AbbVie savings card to reduce copay to $0. This is the most cost-effective path for insured patients and preserves access to FDA-validated manufacturing.

Step 2. If uninsured and income qualifies, apply for myAbbVie Assist. Income at or below 600% of the federal poverty level qualifies for the full patient assistance program, which provides AndroGel at no cost. Processing typically takes 2 to 3 weeks after application approval.

Step 3. If insured but unaffordable, or uninsured and income-ineligible for patient assistance, order compounded testosterone gel. Select a Kentucky-licensed 503A pharmacy that provides a certificate of analysis for each lot. Confirm the testosterone concentration matches the prescribed dose (1.62% is standard; some compounders offer 2% for once-daily dosing in a smaller volume). Monthly cost is typically $90, $130.

Step 4. Order baseline and follow-up labs. Regardless of the product chosen, check serum total testosterone (drawn before 10 a.m.), hematocrit, PSA, and LH/FSH at baseline, then at 3 months, 6 months, and annually. The Endocrine Society's 2018 guideline states: "We recommend measuring testosterone levels 3 to 6 months after treatment initiation to assess whether serum testosterone levels have reached the mid-normal range."

Step 5. Adjust dose based on trough testosterone. Apply gel in the morning to shoulders or upper arms. Measure serum testosterone 2 to 8 hours after application to capture peak or near-peak levels for AndroGel 1.62%. If trough (pre-application) levels are below 400 ng/dL, discuss dose titration with the prescriber before the next refill.

Practical Cost Comparison: All Pathways in Kentucky

The table below summarizes the monthly cost for testosterone gel therapy in Kentucky across each pricing pathway in 2026.

| Pathway | Monthly Cost (Approximate) | |---|---| | AndroGel 1.62% at AbbVie list price | $510 | | AndroGel with GoodRx at major KY chains | $290, $480 | | AndroGel with commercial insurance (Tier 3) | $60, $180 (after deductible) | | AndroGel with AbbVie savings card (commercially insured) | $0, $15 | | AndroGel via myAbbVie Assist (income-qualifying, uninsured) | $0 | | Compounded testosterone gel (503A pharmacy, KY) | $90, $130 | | Testosterone cypionate injection (Kentucky Medicaid) | $15, $30 |

The $390 monthly spread between the AbbVie list price and a 503A compounded gel is the single most actionable data point for uninsured Kentucky men considering TRT. Over 12 months, that difference reaches $4,680. A 2022 Health Affairs analysis found that cost-related non-adherence to hormone therapy affects roughly 14% of commercially insured patients when monthly out-of-pocket exceeds $100, a threshold many Kentucky patients hit before applying available savings programs.

Monitoring Requirements Kentucky Prescribers Must Follow

Prescribing testosterone gel in Kentucky requires adherence to both federal Schedule III controlled substance documentation rules and clinical monitoring standards from major endocrinology societies. The FDA's risk evaluation and mitigation strategy (REMS) for testosterone products requires labeling that warns of secondary exposure risk to women and children through skin contact.

Per Endocrine Society 2018 clinical practice guidelines, prescribers must:

• Confirm diagnosis with two morning testosterone measurements below 300 ng/dL before initiating therapy.
• Check hematocrit at 3 months, 6 months, and annually; withhold or reduce dose if hematocrit exceeds 54%.
• Measure PSA at 3 to 6 months after initiation and annually in men over 40; withhold therapy if PSA rises more than 1.4 ng/mL within any 12-month period.
• Assess bone mineral density by DXA at baseline in men with hypogonadism-associated osteoporosis risk, and recheck at 1 to 2 years if osteoporosis is present.
• Evaluate cardiovascular risk factors (lipid panel, blood pressure, BMI) at baseline and annually.

Kentucky Schedule III prescribing rules require a valid practitioner-patient relationship, written or electronic prescriptions with the DEA registration number, and a maximum 90-day supply per prescription. Refills for Schedule III substances are limited to five within 6 months of the original prescription date per federal law. DEA Schedule III prescribing regulations are codified at 21 CFR 1306.

Finding a Testosterone Prescriber in Kentucky

Men in Louisville, Lexington, Bowling Green, Owensboro, and rural Kentucky can access TRT evaluation through several channels. Board-certified urologists, endocrinologists, and men's health-focused primary care physicians in the state's major cities typically offer in-person TRT evaluation. Wait times at academic centers such as the University of Kentucky's urology department or University of Louisville Health can run 4 to 8 weeks for new patients.

Telehealth platforms, including HealthRX, offer initial consultations within 2, 5 business days. After a HealthRX telehealth visit, prescriptions route directly to the patient's preferred pharmacy in Kentucky. Lab orders go to LabCorp or Quest draw sites statewide, with results returning electronically to the prescriber typically within 24 to 48 hours.

The American Association of Clinical Endocrinology (AACE) hypogonadism guideline recommends that patients with secondary hypogonadism (low testosterone with inappropriately low or normal LH/FSH) receive pituitary MRI before initiating TRT to exclude a pituitary adenoma. This step should not be skipped even in a telehealth setting; it is a prerequisite for responsible prescribing.